• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.

作者信息

Sgherza Nicola, Curci Paola, Rizzi Rita, Battisti Olga, Perfetto Alberto, Weigl Stefania, Larocca Angela M V, Chironna Maria, Tafuri Silvio, Musto Pellegrino

机构信息

Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy.

Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.

出版信息

Ann Hematol. 2024 Jan;103(1):351-355. doi: 10.1007/s00277-023-05484-z. Epub 2023 Oct 2.

DOI:10.1007/s00277-023-05484-z
PMID:37782371
Abstract
摘要

相似文献

1
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.接受三剂或更多剂抗SARS-CoV-2疫苗后多发性骨髓瘤患者突破性COVID-19的临床结局：一项64例的单中心分析
Ann Hematol. 2024 Jan;103(1):351-355. doi: 10.1007/s00277-023-05484-z. Epub 2023 Oct 2.
2
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.多发性骨髓瘤患者接种 3 剂 mRNA 疫苗后对 SARS-CoV-2 变异体的中和能力和 CD8+ T 细胞反应受损：与突破性感染的相关性。
Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173.
3
Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.免疫接种三剂后和突破性 COVID-19 感染前癌症患者 SARS-CoV-2 抗体水平的定量分析。
Curr Oncol. 2022 Sep 28;29(10):7059-7071. doi: 10.3390/curroncol29100554.
4
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.多发性骨髓瘤患者对 COVID-19 mRNA 疫苗的反应与对照组相比是保守的，但受到了损害。
J Hematol Oncol. 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2.
5
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.研究癌症患者接种第三和第四剂 COVID-19 疫苗的免疫反应效果和持久性：一项单臂临床试验。
Elife. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694.
6
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
7
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
8
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.接种灭活 SARS-CoV-2 疫苗后突破性病例的免疫特征和临床结局。
Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021.
9
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.多发性骨髓瘤患者对 SARS-CoV-2 mRNA COVID-19 疫苗的临床保护反应较低。
Int J Hematol. 2022 May;115(5):737-747. doi: 10.1007/s12185-022-03300-4. Epub 2022 Feb 21.
10
Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.最后一剂 COVID-19 疫苗接种时间和完全（加强）接种疫苗的医护人员中的 SARS-CoV-2 突破感染。
J Hosp Infect. 2023 Feb;132:46-51. doi: 10.1016/j.jhin.2022.11.016. Epub 2022 Dec 5.

引用本文的文献

1
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.多发性骨髓瘤患者接种第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的体液和细胞免疫反应随访
Front Immunol. 2025 Feb 18;16:1532947. doi: 10.3389/fimmu.2025.1532947. eCollection 2025.
2
Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments.根据B/T/NK淋巴细胞绝对计数和抗CD38治疗情况，多发性骨髓瘤“加强针”接种患者对SARS-CoV-2突破性感染的抗体反应
Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024022. doi: 10.4084/MJHID.2024.022. eCollection 2024.

本文引用的文献

1
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
2
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析：替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
3
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
超高风险多发性骨髓瘤患者经密集抗 CD38 抗体治疗后对 COVID-19 加强疫苗接种的免疫反应：来自英国骨髓瘤（MUK）九项 OPTIMUM 试验的结果。
Br J Haematol. 2023 Jun;201(5):845-850. doi: 10.1111/bjh.18714. Epub 2023 Mar 9.
4
Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis.多发性骨髓瘤患者的 SARS-CoV-2 疫苗免疫原性：系统评价和荟萃分析。
Blood Adv. 2022 Dec 27;6(24):6198-6207. doi: 10.1182/bloodadvances.2022008530.
5
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.接受第四剂抗SARS-CoV-2疫苗的血液系统恶性肿瘤患者中COVID-19临床结局改善：一项EPICOVIDEHA报告。
Hemasphere. 2022 Oct 25;6(11):e789. doi: 10.1097/HS9.0000000000000789. eCollection 2022 Nov.
6
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy.第二剂BNT162b2加强针可恢复多发性骨髓瘤患者的新冠病毒体液免疫反应，但接受抗BCMA治疗的患者除外。
Hemasphere. 2022 Jul 29;6(8):e764. doi: 10.1097/HS9.0000000000000764. eCollection 2022 Aug.
7
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.骨髓瘤患者第三次接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的体液免疫和细胞免疫反应增强及病毒中和作用
Cancer Cell. 2022 May 9;40(5):441-443. doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6.
8
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.骨髓瘤患者接种 SARS-CoV-2 疫苗后中和抗体反应的决定因素。
J Clin Oncol. 2022 Sep 10;40(26):3057-3064. doi: 10.1200/JCO.21.02257. Epub 2022 Mar 8.
9
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.COVID-19 疫苗接种在多发性骨髓瘤患者中的应用：欧洲骨髓瘤网络共识。
Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
10
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.